Insulin Lispro
Brand name: Humalog Kwikpen U-100
Rank #28 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$623.9M
Total Cost
854,813
Total Claims
$623.9M
Total Cost
30,793
Prescribers
$730
Cost per Claim
141,554
Beneficiaries
1,393,348
30-Day Fills
$20K
Avg Cost/Provider
28
Avg Claims/Provider
Share of Medicare Part D Spending
0.23%
of total Medicare Part D spending
$623.9M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $623.9M total
🔎 Data Overview
Ranked #28 out of 500 drugs tracked by total cost. Insulin Lispro represents a significant portion of Medicare drug spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Insulin Lispro
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Brian Burtch | Endocrinology | Mentor, OH | 404 | $775K |
| 2 | Katherine Montoto | Nurse Practitioner | Jefferson City, TN | 322 | $720K |
| 3 | Carlos Martinez Rivera | Endocrinology | Mayaguez, PR | 818 | $653K |
| 4 | Ahmed Al Jebawi | Endocrinology | Anderson, IN | 406 | $614K |
| 5 | Steven Cowart | Endocrinology | Huntsville, AL | 434 | $571K |
| 6 | Bobby Johnson | Endocrinology | Huntsville, AL | 410 | $565K |
| 7 | Priya Menon | Endocrinology | Danville, IN | 274 | $547K |
| 8 | Jasjeet Kaur | Endocrinology | Glendale, AZ | 394 | $531K |
| 9 | Stacy Congdon | Nurse Practitioner | Johnson City, NY | 235 | $512K |
| 10 | Mohamed Zeitoun | Endocrinology | Hobart, IN | 243 | $493K |
| 11 | Ronald Iverson | Endocrinology | Dubuque, IA | 288 | $482K |
| 12 | Oscar Ortiz | Endocrinology | Toms River, NJ | 361 | $471K |
| 13 | K. Thampy | Endocrinology | Saint Louis, MO | 249 | $469K |
| 14 | Mohammad Ijaz | Endocrinology | Zanesville, OH | 323 | $455K |
| 15 | Vasdev Lohano | Endocrinology | Washington, IN | 429 | $448K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 25 | Ruxolitinib Phosphate (Jakafi) | $698.1M | 46,655 |
| 26 | Cyclosporine (Restasis) | $684.1M | 723,620 |
| 27 | Linaclotide (Linzess) | $639.4M | 823,023 |
| 28 | Insulin Lispro (Humalog Kwikpen U-100) | $623.9M | 854,813 |
| 29 | Dupilumab (Dupixent Pen) | $609.1M | 156,267 |
| 30 | Rsvpref3 Antigen/As01e/Pf (Arexvy) | $608.6M | 1,935,431 |
| 31 | Pomalidomide (Pomalyst) | $589.0M | 27,253 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology